Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 16;37(5):1068–1079. doi: 10.1038/s41375-023-01867-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Normal human monocytes were treated with increasing concentration of ERK1/2 inhibitor Ulixertinib. A Western blot analysis of phospho-RSK3 protein levels in monocyte after Ulixertinib treatment. B Monocytes viability was evaluated using XTT assay after 72 h of treatment. C SPP1 mRNA expression was evaluated by means of real time qRT-PCR after 72 h of treatment. OPN production by monocytes was assessed by means of ELISA (Enzyme-linked immunosorbent assay) in culture supernatants at 72 (D) and 96 hours (E) of treatment. Histograms represent the mean values while bars indicate the standard deviation. Comparisons were performed by means of one-way ANOVA. *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001; ****: P ≤ 0.0001 Abbreviations: SPP1 osteopontin; RQ relative quantity; OPN osteopontin; Ulix Ulixertinib.